Introduction: Oncogenic-addicted non-small cell lung cancer (NSCLC) has emerged as the most prevalent form of lung cancer, presenting a dynamic landscape in treatment modalities. Among these, epidermal growth factor receptor (EGFR)-mutant NSCLC remains the predominant oncogenic mutation, particularly prevalent in regions such as Asia and Latin America. Case Presentation: This case study highlights the experience of a woman diagnosed with EGFR-sensitive (del exon 19) mutant NSCLC who demonstrated an extended duration of response to third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy. Upon disease progression, detection of MET gene amplification prompted the addition of a selective MET inhibitor to the existing EGFR-TKI regimen, resulting in a complete response for the patient. Discussion: The molecular heterogeneity of this condition has significantly increased in complexity over recent years, marked by the identification of baseline co-alterations and development of a broad spectrum of resistance mechanisms post-EGFR-TKI therapy. This complexity poses a substantial challenge to clinicians. Despite the rapid advancement of targeted therapies and the implementation of treatment escalation through combination strategies, there remains an ongoing debate regarding which patients would benefit most from combination therapies, both in the initial treatment phase and in the setting of disease progression, particularly when off-target resistance mechanisms or co-alterations are identified.

1.
Tan
CS
,
Kumarakulasinghe
NB
,
Huang
YQ
,
Ang
YLE
,
Choo
JR
,
Goh
BC
, et al
.
Third generation EGFR TKIs: current data and future directions
.
Mol Cancer
.
2018
;
17
(
1
):
29
.
2.
Feldt
SL
,
Bestvina
CM
.
The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications
.
Cancers
.
2023
;
15
(
11
):
2998
.
3.
Wang
Q
,
Yang
S
,
Wang
K
,
Sun
SY
.
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
.
J Hematol Oncol
.
2019
;
12
(
1
):
63
.
4.
Qin
K
,
Hong
L
,
Zhang
J
,
Le
X
.
MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities
.
Cancers
.
2023
;
15
(
3
):
612
.
5.
Pikor
LA
,
Ramnarine
VR
,
Lam
S
,
Lam
WL
.
Genetic alterations defining NSCLC subtypes and their therapeutic implications
.
Lung Cancer
.
2013
;
82
(
2
):
179
89
.
6.
Scagliotti
G
,
Hanna
N
,
Fossella
F
,
Sugarman
K
,
Blatter
J
,
Peterson
P
, et al
.
The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies
.
Oncologist
.
2009
;
14
(
3
):
253
63
.
7.
Paez
JG
,
Jänne
PA
,
Lee
JC
,
Tracy
S
,
Greulich
H
,
Gabriel
S
, et al
.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
.
Science
.
2004
;
304
(
5676
):
1497
500
.
8.
Arrieta
O
,
Cardona
AF
,
Martín
C
,
Más-López
L
,
Corrales-Rodríguez
L
,
Bramuglia
G
, et al
.
Updated frequency of EGFR and KRAS mutations in NonSmall-cell lung cancer in Latin America: the Latin-American consortium for the investigation of lung cancer (CLICaP)
.
J Thorac Oncol
.
2015
;
10
(
5
):
838
43
.
9.
Fukuoka
M
,
Wu
Y-L
,
Thongprasert
S
,
Sunpaweravong
P
,
Leong
S-S
,
Sriuranpong
V
, et al
.
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS)
.
J Clin Oncol
.
2011
;
29
(
21
):
2866
74
.
10.
Hata
A
,
Katakami
N
,
Yoshioka
H
,
Takeshita
J
,
Tanaka
K
,
Nanjo
S
, et al
.
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations
.
Cancer
.
2013
;
119
(
24
):
4325
32
.
11.
Pao
W
,
Miller
VA
,
Politi
KA
,
Riely
GJ
,
Somwar
R
,
Zakowski
MF
, et al
.
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
.
PLoS Med
.
2005
;
2
(
3
):
e73
.
12.
Hochmair
MJ
,
Buder
A
,
Schwab
S
,
Burghuber
OC
,
Prosch
H
,
Hilbe
W
, et al
.
Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib
.
Target Oncol
.
2019
;
14
(
1
):
75
83
.
13.
Fan
Y
,
Sun
R
,
Wang
Z
,
Zhang
Y
,
Xiao
X
,
Liu
Y
, et al
.
Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
.
J Cancer Res Clin Oncol
.
2023
;
149
(
5
):
1667
77
.
14.
Mehlman
C
,
Cadranel
J
,
Rousseau-Bussac
G
,
Lacave
R
,
Pujals
A
,
Girard
N
, et al
.
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study
.
Lung Cancer
.
2019
;
137
:
149
56
.
15.
Choudhury
NJ
,
Marra
A
,
Sui
JSY
,
Flynn
J
,
Yang
SR
,
Falcon
CJ
, et al
.
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
.
J Thorac Oncol
.
2023
;
18
(
4
):
463
75
.
16.
Peng
LX
,
Jie
GL
,
Li
AN
,
Liu
SY
,
Sun
H
,
Zheng
MM
, et al
.
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
.
Exp Hematol Oncol
.
2021
;
10
(
1
):
52
.
17.
Zheng
Q
,
Lin
X
,
Qi
W
,
Yin
J
,
Li
J
,
Wang
Y
, et al
.
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multicenter study in China
.
Lung Cancer
.
2024
;
194
:
107897
.
18.
Mok
TS
,
Wu
Y-L
,
Ahn
M-J
,
Garassino
MC
,
Kim
HR
,
Ramalingam
SS
, et al
.
Osimertinib or platinum-pemetrexed in EGFR T790m-positive lung cancer
.
N Engl J Med
.
2017
;
376
(
7
):
629
40
.
19.
Yu
HA
,
Sima
CS
,
Huang
J
,
Solomon
SB
,
Rimner
A
,
Paik
P
, et al
.
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
.
J Thorac Oncol
.
2013
;
8
(
3
):
346
51
.
20.
Leonetti
A
,
Sharma
S
,
Minari
R
,
Perego
P
,
Giovannetti
E
,
Tiseo
M
.
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
.
Br J Cancer
.
2019
;
121
(
9
):
725
37
.
21.
F Smit
E
,
Dooms
C
,
Raskin
J
,
Nadal
E
,
Tho
LM
,
Le
X
, et al
.
Insight 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance
.
Future Oncol
.
2022
;
18
(
9
):
1039
54
.
You do not currently have access to this content.